CA9-Targeted Liposomal Delivery of siETS1 Inhibits Clear Cell Renal Cell Carcinoma Progression by Disrupting the ETS1/MYC Regulatory Axis - PubMed
2 hours ago
- #Renal Cell Carcinoma
- #Nanomedicine
- #Targeted Therapy
- The study identifies the ETS1/MYC regulatory axis as a key driver of clear cell renal cell carcinoma (ccRCC) progression, with high levels correlating with poorer prognosis.
- A targeted nanoplatform, ETS1@Lip-CAIX, was developed using CA9-targeted liposomal nanoparticles loaded with siETS1 to disrupt the ETS1/MYC axis, showing high siRNA encapsulation efficiency and stability.
- In vitro and in vivo evaluations, including patient-derived organoids and mouse xenografts, demonstrated significant tumor growth inhibition with no observed toxicity to normal tissues.
- The research provides a novel therapeutic strategy for ccRCC, combining a newly identified molecular target with a precise, biocompatible nanomedicine approach for potential personalized treatment.